康寧傑瑞製藥-B(09966.HK)將於2021年ESMO大會呈列KN046及KN026研究進展摘要及電子海報
格隆匯7月26日丨康寧傑瑞製藥-B(09966.HK)發佈公吿,公司將於2021年歐洲腫瘤內科學會大會(“2021年ESMO大會”)以摘要及電子海報形式呈列發佈KN046(一種抗PD-L1/CTLA-4雙特異性抗體)及KN026(一種HER2靶向雙特異性抗體)的研究進展,歐洲腫瘤內科學會大會為一個具影響力的歐洲腫瘤學平台,為來自世界各地的臨牀醫生、研究人員、患者倡議者、記者及醫療行業代表而設計。摘要將於2021年9月13日零時五分(歐洲中部夏令時間(CEST))及電子海報呈列材料將於2021年9月16日(為2021年ESMO大會舉行時間)於公司網站http://www.alphamabonc.com 相應公佈。
KN046是集團自主研發的全球性首創雙特異性抗體,同時靶向PD-L1及CTLA-4,具有明顯的結構差異以改善腫瘤微環境的定位並降低脱靶毒性。目前,KN046在中國、美國及澳大利亞已開展約20項不同階段的不同聯合用藥方案臨牀試驗,覆蓋十多種不同的癌症適應症,包括NSCLC、TNBC、ESCC、HCC、PDAC及胸腺癌等。該等臨牀試驗結果初步顯示出KN046具有高耐受性和良好活性。基於在中國及澳大利亞取得的臨牀結果,美國食品藥品監督管理局已批准於美國進行一項KN046的關鍵性試驗,並已就KN046授予孤兒藥資格,用於治療胸腺上皮腫瘤。目前,旨在評估KN046聯合含鉑化療對局部晚期不可切除或轉移性鱗狀NSCLC患者的療效及安全性的III期臨牀試驗已在中國啟動。KN046的臨牀前及臨牀試驗結果展現出良好的療效,並表明可顯著減少對人體外周系統可能產生的毒副作用。公司認為,KN046有望成為突破性腫瘤免疫特效藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.